-
Mashup Score: 2Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis - 3 year(s) ago
Anakinra could be a safe, anti-inflammatory treatment option to reduce the mortality risk in patients admitted to hospital with moderate to severe COVID-19 pneumonia, especially in the presence of signs of hyperinflammation such as CRP concentrations higher than 100 mg/L.
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 1
Anakinra treatment may reduce mortality risk in patients with moderate-to-severe COVID-19, especially for those with hyperinflammation.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet-
#Anakinra treatment may reduce mortality risk in patients with moderate-to-severe #COVID19. The safe, anti-inflammatory treatment is especially useful when patients present symptoms of hyperinflammation. https://t.co/Q9RKTtPaB7
-
-
Mashup Score: 11
Anakinra treatment may reduce mortality risk in patients with moderate-to-severe COVID-19, especially for those with hyperinflammation.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet-
#Anakinra treatment may reduce mortality risk in patients with moderate-to-severe #COVID19, especially for those with hyperinflammation. #rheumtwitter https://t.co/UFSJhWWsxY
-
-
Mashup Score: 0'Influx of newer agents' in gout pipeline hold promise for shifting treatment paradigm - 3 year(s) ago
Although allopurinol, febuxostat and pegloticase are still relied on to do the heavy lifting in lowering urate for patients with gout, an “influx of newer agents” may help expand effective disease management, according to a presenter here.“In the 21st century, we often think that RA is the most common condition — why? Because we have so many different medications available
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
#Allopurinol and #pegloticase are still needed to do the heavy lifting in lowering #urate for #gout patients, but new agents in the #DrugPipeline - like #anakinra #verinurad and #arhalofenate - could expand the treatment toolbox #CCR21 #CCREast21 https://t.co/fsOQ7sNnjM
-
-
Mashup Score: 0Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis - 3 year(s) ago
Anakinra could be a safe, anti-inflammatory treatment option to reduce the mortality risk in patients admitted to hospital with moderate to severe COVID-19 pneumonia, especially in the presence of signs of hyperinflammation such as CRP concentrations higher than 100 mg/L.
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet-
NEW RESEARCH—Effect of #anakinra on mortality in patients with #COVID19: a systematic review and patient-level meta-analysis https://t.co/xUExvyhi1X #LancetRheumatology https://t.co/pVBefCoK0E
-
-
Mashup Score: 1
Anakinra safely reduces the need for invasive mechanical ventilation and mortality risk in patients with COVID-19 who are hospitalized, but non-intubated, according to a meta-analysis published in Rheumatology. “A subgroup of SARS-CoV-2 infected patients manifest hyperinflammatory symptoms that resemble the cytokine storm syndromes characterized by increased release of chemokines, growth
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
“ #Anakinra reduces the need for invasive mechanical #ventilation and lowers mortality risk in hospitalized non-intubated patients with #COVID19 without increasing the risk of adverse events, such as liver dysfunction or bacteremia...” https://t.co/nHBhNjOlFE https://t.co/ol6lWVlQU7
-
-
Mashup Score: 1
Anakinra safely reduces the need for invasive mechanical ventilation and mortality risk in patients with COVID-19 who are hospitalized, but non-intubated, according to a meta-analysis published in Rheumatology. “A subgroup of SARS-CoV-2 infected patients manifest hyperinflammatory symptoms that resemble the cytokine storm syndromes characterized by increased release of chemokines, growth
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
#Anakinra safely reduces the need for invasive mechanical ventilation and mortality risk in patients with #COVID19 who are hospitalized, but non-intubated, said researchers @Ioannina_Univ https://t.co/nHBhNjOlFE
-
-
Mashup Score: 0IL-1, IL-6 Inhibition in Patients With COVID-19 and Hyperinflammation Assessed - Infectious Disease Advisor - 3 year(s) ago
Researchers evaluated the effect of treatment with an IL-1 and IL-6 inhibitors in hospitalized patients with COVID-19 and hyperinflammation.
Source: Infectious Disease AdvisorCategories: Infectious Disease, Latest HeadlinesTweet-
Study researchers noted that treatment with IL-1 inhibitor #anakinra significantly reduced mortality in patients with COVID-19. https://t.co/VCmMX6DxsK
-
-
Mashup Score: 0
Although anakinra is not superior to triamcinolone in affecting gout pain intensity over 24 to 72 hours, it is comparable in pain reduction and even favored in most secondary outcomes, according to data published in Arthritis & Rheumatology.“Anti-inflammatory drugs used for treatment of gout flares include NSAIDs, colchicine and glucocorticoids,” Kenneth G. Saag, MD, of the
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
New research in Arthritis & Rheumatology reported that #anakinra was comparable to triamcinolone for reducing #gout flare #pain https://t.co/ynPWBaAbvG
-
-
Mashup Score: 0
Although anakinra is not superior to triamcinolone in affecting gout pain intensity over 24 to 72 hours, it is comparable in pain reduction and even favored in most secondary outcomes, according to data published in Arthritis & Rheumatology.“Anti-inflammatory drugs used for treatment of gout flares include NSAIDs, colchicine and glucocorticoids,” Kenneth G. Saag, MD, of the
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
Although #anakinra is not superior to triamcinolone in affecting #gout pain intensity over 24 to 72 hours, it is comparable in pain reduction and even favored in most secondary outcomes, said researchers @uabmedicine https://t.co/MoCbmlf1nQ
-
ICYMI, in our October issue—Effect of #anakinra on mortality in patients with #COVID19: a systematic review and patient-level meta-analysis https://t.co/xUExvyhi1X https://t.co/Pba7rYyENZ